Biogen (BIIB) Operating Margin (2009 - 2026)
Biogen (BIIB) recorded quarterly Operating Margin of 11.43% in Q1 2026, up 52.74% quarter-over-quarter from 24.19% in Q4 2025, and up 165.0% on a YoY basis from 4.31% in Q1 2025.
Biogen (BIIB) Operating Margin (2009 - 2026) Analysis & Trends
Biogen's Operating Margin history runs 18 years deep, the most recent figure standing at 11.43% for Q1 2026.
- In Q1 2026, Operating Margin rose 165.0% year-over-year to 11.43%; the TTM figure through Mar 2026 stood at 8.18% (down 161.0% YoY), while the FY2025 annual figure was 8.57%, down 439.0% from the prior year.
- Operating Margin was 11.43% for Q1 2026 at Biogen, up from 24.19% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 35.94% in Q3 2022 to a low of 31.65% in Q3 2023.
- Historically, Operating Margin has averaged 0.72% across 5 years, with a median of 3.38% in 2024.
- The sharpest annual moves came in 2023 and 2024: Operating Margin plunged 6759 bps in 2023, then surged 2404 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 17.29% in 2022, then slumped by 69 bps to 5.35% in 2023, then tumbled by 322 bps to 11.9% in 2024, then slumped by 103 bps to 24.19% in 2025, then soared by 53 bps to 11.43% in 2026.
- The last three Operating Margin figures came in at 11.43% (Q1 2026), 24.19% (Q4 2025), and 4.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.58% |
| 10 | Biogen | 28.97 Bn | 24.68 Bn | 1.82 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.43% |
| Dec 31, 2025 | -24.19% |
| Sep 30, 2025 | -4.62% |
| Jun 30, 2025 | 5.25% |
| Mar 31, 2025 | -13.09% |
| Dec 31, 2024 | -11.90% |
| Sep 30, 2024 | -7.61% |
| Jun 30, 2024 | 6.19% |
| Mar 31, 2024 | -3.38% |
| Dec 31, 2023 | 5.35% |
| Sep 30, 2023 | -31.65% |
| Jun 30, 2023 | 4.70% |
| Mar 31, 2023 | -9.11% |
| Dec 31, 2022 | 17.29% |
| Sep 30, 2022 | 35.94% |
| Jun 30, 2022 | 30.34% |
| Mar 31, 2022 | 24.12% |
| Dec 31, 2021 | 21.48% |
| Sep 30, 2021 | 28.57% |
| Jun 30, 2021 | 17.50% |